Discovery of highly selective and potent CYP1B1 inhibitors for overcoming paclitaxel resistance in A549/Taxol cells. (PubMed, Eur J Med Chem) - Jul 5, 2026 - "Our research group previously identified W-1, a key intermediate of Fexuprazan, as an inhibitor of CYP1B1 (IC50 = 0.16 μM). In the A549/Taxol drug-resistant cell model, C27 significantly enhanced the inhibitory effect of paclitaxel on the proliferation of resistant cells and effectively inhibited tumor cell migration and invasion. Pharmacokinetic studies revealed that C27 displayed good plasma stability and liver microsomal stability, with observable systemic exposure following both oral and intravenous administration in mice."
Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CYP1B1
|
|
Bohou Song; Dihan Tan; Haoyu Zhang; Maosheng Cheng; Ningyi Qin; Ting Wang; Xiaoqiu Liu; Yujiang Fu
|